Transgene confirms the potential of its two innovative platforms and expects significant clinical results in 2022

information fournie par Boursorama CP •16/03/2022 à 17:45

2021 Full-year results and business update

­- TG4050 (myvac®): First positive results from the two Phase I trials. Additional data to be presented at AACR 2022 in April.
­- TG4001: First patient enrolled in Phase II study in June 2021. Active patient recruitment in Europe and trial initiation in the US. Interim analysis expected in Q4 2022.
­- BT-001 (Invir.IO™): IND approval for Phase I/IIa trial in the US, ongoing enrollment in Europe. Next clinical update in Q2 2022.
­- TG6002: Clinical proof-of-concept of the intravenous administration of an oncolytic virus presented at major congresses in 2021. End of Phase I expected in mid-2022.
­- AstraZeneca collaboration (Invir.IO™): First option license for an oncolytic virus exercised in 2021. R&D collaboration to develop additional candidates ongoing.
­- €49.6 million cash available at year-end 2021 providing financial visibility until end of 2023.


Conference call in English scheduled today at 6:00 p.m. CET (details at the end of the release)

..../...